ArticleAmerican journal of preventive cardiology2026
Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation is causally implicated in the development and progression of atherosclerotic cardiovascular disease, but clinical trials of anti-inflammatory therapies have yielded inconsistent effects on cardiovascular outcomes. Methods: We conducted a systematic review and meta-analysis to evaluate the cardiovascular efficacy and safety of a broad range of anti-inflammatory agents. Medline, Embase and Cochrane databases were searched from inception to 08 October 2024 for randomised controlled trials evaluating the effect of anti-inflammatory therapies on a primary cardiovascular outcome with at least 100 patient-years follow-up per treatment arm. Trial level meta-analysis was performed using a random effects model. The primary outcome was major adverse cardiovascular events (MACE); other outcomes included myocardial infarction, stroke, heart failure, serious adverse events, infection, and malignancy. Results: Thirteen trials enrolling 82,208 participants were included. The effect of anti-inflammatory agents on MACE varied by drug class (P-heterogeneity=0.049), driven primarily by benefits observed with colchicine (RR 0.76; 95 % CI 0.65-0.90; moderate certainty) and canakinumab (RR 0.88; 95 % CI 0.79-0.97; moderate certainty), with no benefit observed for other agents. Among colchicine trials, heterogeneity was identified (P-heterogeneity=0.003), and subgroup analyses suggested greater benefit in coronary artery disease and/or recent myocardial infarction trials (P-heterogeneity=0.068). Safety outcomes also varied by drug class, with significant heterogeneity in serious adverse events (P-heterogeneity=0.005), largely attributable to methotrexate, and some evidence of heterogeneity for infection (P-heterogeneity=0.076) and malignancy (P-heterogeneity=0.077). Conclusion: Some anti-inflammatory agents may reduce the risk of cardiovascular outcomes, but their effects appear to vary substantially across drug classes, with important differences in both efficacy and safety. These findings underscore the need for rigorous evaluation of new anti-inflammatory therapeutics to ascertain benefits and harms across different populations and therapeutic indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.